Obesity is a chronic recurring disease whose prevalence has almost tripled over the past 40
years. In individuals with obesity, there is significant increased risk of morbidity and mortality …

Glucagon-like peptide-1 (GLP-1) is currently one of the most promising biological systems
for the development of effective obesity pharmacotherapies. Long-acting GLP-1 analogs …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Glucagon-like peptide 1 (GLP-1) and GLP-1 analogs have received much recent attention
due to the success of GLP-1 mimetics in treating type II diabetes mellitus (T2DM), but these …

This review considers the similarities and differences between the physiological systems
regulated by gut‐derived and neuronally produced glucagon‐like peptide 1 (GLP‐1). It …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications
to reduce appetite and body weight. These actions are centrally mediated; however, the …

Glucagon-like-peptide-1 (GLP-1) and its long acting analogs comprise a novel class of type
2 diabetes (T2D) treatment. What makes them unique among other T2D drugs is their …

The glucagon-like peptide-1 (GLP-1) system is physiologically involved in the control of
energy balance and blood glucose homeostasis. Thus, GLP-1-based pharmaceuticals are …

Here, we provide a focused review of the evidence for the roles of the vagus nerve in
mediating the regulatory effects of peripherally and centrally produced GLP‐1 on eating …

The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut
enteroendocrine cells and brain preproglucagon (PPG) neurons, which, respectively, define …